ReviewInternational journal of molecular sciences2019
The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.Nature reviews. Gastroenterology & hepatology · 2026Review
- Ammonium Hydroxide Enhancement of Dietary Protein in High-Fat Diets Modulates Liver Metabolism Signaling in a Sex- and Age-Dependent Manner in C3H/HeJ Mice.International journal of molecular sciences · 2025Article
- Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?Cell biochemistry and biophysics · 2025Review
- HCC-Related lncRNAs: Roles and Mechanisms.International journal of molecular sciences · 2024Review
- The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.Nature reviews. Gastroenterology & hepatology · 2023Review
- Review
- [Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)].Zeitschrift fur Gastroenterologie · 2023Article
- Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- Hydrogels for localized chemotherapy of liver cancer: a possible strategy for improved and safe liver cancer treatment.Drug delivery · 2022Article
- Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective.Hepatobiliary surgery and nutrition · 2022Article
- Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials.Bioengineering (Basel, Switzerland) · 2022Review
- Hepatic PEMT Expression Decreases with Increasing NAFLD Severity.International journal of molecular sciences · 2022Article
- Transcriptome changes in stages of non-alcoholic fatty liver disease.World journal of hepatology · 2022Article
- Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.World journal of gastroenterology · 2022Review
- Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Article
- Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.Journal of hepatocellular carcinoma · 2022Review
- Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies.Frontiers in pharmacology · 2022Review
- Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2.Bioengineered · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the Western world, and the occurrence of its complications, such as hepatocellular carcinoma (HCC), has rapidly increased. Obesity and diabetes are considered not only the main triggers for the development of the disease, but also two independent risk factors for HCC. Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression. Therefore, an appropriate follow-up of these patients is needed for the early diagnosis and treatment of HCC. To date, international guidelines recommend the use of ultrasonography with or without alpha-fetoprotein (AFP) in patients with advanced fibrosis. Furthermore, the use of non-invasive tools could represent a strategy to implement surveillance performance. In this review, we analyzed the main risk factors of NAFLD-related HCC, the validated screening methods and the future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.